观点新冠疫苗

Time for other vaccine makers to follow Oxford/AstraZeneca’s lead

We at the university, alongside the drugmaker, felt we should not profiteer from a pandemic

The writer is vice-chancellor of the University of Oxford

Over a year ago, Oxford university scientists anticipated the potential impact of the emerging coronavirus and believed that they might be able to produce an effective vaccine. The speed with which they were able to do so was due, in part, to 20 years’ worth of work on infectious disease with colleagues in Africa and Asia. Given their experience in the developing world, they knew just how devastating a global pandemic would be in poor countries and what a risk this would pose to the rest of the world.

Many of their worst fears are coming true. Globally, we may have not yet reached the peak of the pandemic; the death toll could exceed 9m by September. The heart-rending scenes from India showing the devastating consequences of Covid-19 pose a challenge to the conscience of the world.

您已阅读18%(848字),剩余82%(3831字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×